24 Jul, EOD - Indian

SENSEX 80148.88 (-0.35)

Nifty 50 24413.5 (-0.27)

Nifty Bank 51317 (-0.89)

Nifty IT 40115.05 (0.18)

Nifty Midcap 100 56872.75 (1.04)

Nifty Next 50 71844.65 (0.30)

Nifty Pharma 20908.5 (0.74)

Nifty Smallcap 100 18723.5 (1.76)

24 Jul, EOD - Global

NIKKEI 225 39154.85 (-1.11)

HANG SENG 17311.05 (-0.91)

DOW JONES 39923.88 (-1.08)

S&P 5437.6 (-2.13)

Login/Signup

Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(04 Jul 2024, 14:18)

Sun Pharma gains on EMA nod for Nidlegy

Sun Pharmaceuticals advanced 2.31% to Rs 1,568 after the European Medicines Agency (EMA) validated the submission of the marketing authorization application (MAA) for Nidlegy, which was finalized on 3 June 2024.

Nidlegy is partnered with Sun Pharma for the treatment of skin cancers in Europe, New Zealand and Australia.

Dario Neri, chief executive officer and chief scientific officer at Philogen commented, “The validation of the dossier by EMA represents the first important milestone for the MAA review process. Our group is committed to working with EMA throughout the review process with the goal of making Nidlegy available to patients in need."

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with specialty and generic presence and India's top pharma company.

The pharma major’s consolidated net profit jumped 33.77% to Rs 2,654.58 crore on 10.14% growth in revenue from operations to Rs to Rs 11,813.33 crore in Q4 FY24 over Q4 FY23.

More News
More Company News View Company Information